eMedicine Specialties > Otolaryngology and Facial Plastic Surgery > Head & Neck Surgery

Lymphomas of the Head and Neck: Multimedia

Author: Kieron M Dunleavy, MD, Investigator/Attending Physician, National Cancer Institute
Coauthor(s): Erik Kass, MD, Chief, Department of Clinical Otolaryngology, Associates in Otolaryngology of Northern Virginia; Wyndham Wilson, MD, PhD, Senior Investigator, Division of Clinical Sciences, National Institutes of Health National Cancer Institute
Contributor Information and Disclosures

Updated: Dec 18, 2007

Multimedia

CT scan of a patient with a natural killer (NK)/T...
(Enlarge Image)
Media file 1: CT scan of a patient with a natural killer (NK)/T-cell lymphoma of the right nasal cavity and maxillary sinus.
[ CLOSE WINDOW ]
CT scan of a patient with a natural killer (NK)/T...

CT scan of a patient with a natural killer (NK)/T-cell lymphoma of the right nasal cavity and maxillary sinus.

CT scan of the same patient as in Image 1, 6 mont...
(Enlarge Image)
Media file 2: CT scan of the same patient as in Image 1, 6 months after treatment with 4 cycles of DA-EPOCH (ie, infused etoposide, doxorubicin, and vincristine with bolus cyclophosphamide and prednisone).
[ CLOSE WINDOW ]
CT scan of the same patient as in Image 1, 6 mont...

CT scan of the same patient as in Image 1, 6 months after treatment with 4 cycles of DA-EPOCH (ie, infused etoposide, doxorubicin, and vincristine with bolus cyclophosphamide and prednisone).

CT scan of a patient with a recurrence of stage I...
(Enlarge Image)
Media file 3: CT scan of a patient with a recurrence of stage I-AE angiocentric lymphoma of the left maxillary sinus, treated 7 years earlier with 4 cycles of ProMACE-MOPP (ie, prednisone, methotrexate, Adriamycin, cyclophosphamide, etoposide–mechlorethamine [nitrogen mustard], vincristine, procarbazine, and prednisone) and 3960 cGy of radiation.
[ CLOSE WINDOW ]
CT scan of a patient with a recurrence of stage I...

CT scan of a patient with a recurrence of stage I-AE angiocentric lymphoma of the left maxillary sinus, treated 7 years earlier with 4 cycles of ProMACE-MOPP (ie, prednisone, methotrexate, Adriamycin, cyclophosphamide, etoposide–mechlorethamine [nitrogen mustard], vincristine, procarbazine, and prednisone) and 3960 cGy of radiation.

CT scan of the same patient as in Image 3, 2 year...
(Enlarge Image)
Media file 4: CT scan of the same patient as in Image 3, 2 years after salvage therapy.
[ CLOSE WINDOW ]
CT scan of the same patient as in Image 3, 2 year...

CT scan of the same patient as in Image 3, 2 years after salvage therapy.

This feature requires the newest version of Flash. You can download it here.
Media file 5: Fiberoptic nasal examination of a patient with natural killer (NK)/T-cell lymphoma of the right nasal cavity and maxillary sinus, whose CT scans are shown in Images 1 and 2.
[ CLOSE WINDOW ]
Fiberoptic nasal examination of a patient with na...

Fiberoptic nasal examination of a patient with natural killer (NK)/T-cell lymphoma of the right nasal cavity and maxillary sinus, whose CT scans are shown in Images 1 and 2.

More on Lymphomas of the Head and Neck

Overview: Lymphomas of the Head and Neck
Differential Diagnoses & Workup: Lymphomas of the Head and Neck
Treatment & Medication: Lymphomas of the Head and Neck
Follow-up: Lymphomas of the Head and Neck
Multimedia: Lymphomas of the Head and Neck
References
[ CLOSE WINDOW ]

References

  1. [Best Evidence] Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. Jun 20 2005;23(18):4117-26. [Medline].

  2. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. Apr 15 2004;22(8):1454-9. [Medline].

  3. Ahn YC, Lee KC, Kim DY, Huh SJ, Yeo IH, Lim DH. Fractionated stereotactic radiation therapy for extracranial head and neck tumors. Int J Radiat Oncol Biol Phys. Sep 1 2000;48(2):501-5. [Medline].

  4. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. Feb 3 2000;403(6769):503-11. [Medline].

  5. André M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood. Sep 15 1998;92(6):1933-40. [Medline].

  6. Aparicio J, Segura A, Garcerá S, Oltra A, Santaballa A, Yuste A. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol. May 1999;10(5):593-5. [Medline].

  7. Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. Mar 15 2003;21(6):1044-9. [Medline].

  8. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. Nov 1 2005;106(9):3183-90. [Medline].

  9. Beaty MM, Funk GF, Karnell LH, Graham SM, McCulloch TM, Hoffman HT. Risk factors for malignancy in adult tonsils. Head Neck. Aug 1998;20(5):399-403. [Medline].

  10. Bessell EM, MacLennan KA, Toghill PJ, Ellis IO, Fletcher J, Dowling FD. Suprahyoid Hodgkin's disease stage IA. Radiother Oncol. Nov 1991;22(3):190-4. [Medline].

  11. Bishop PC, Rao VK, Wilson WH. Burkitt's lymphoma: molecular pathogenesis and treatment. Cancer Invest. 2000;18(6):574-83. [Medline].

  12. Boivin JF, Hutchison GB, Zauber AG, Bernstein L, Davis FG, Michel RP. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst. May 17 1995;87(10):732-41. [Medline].

  13. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. Jul 15 2004;22(14):2835-41. [Medline].

  14. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. Nov 19 1992;327(21):1478-84. [Medline].

  15. Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. Nov 1993;11(11):2258-72. [Medline].

  16. Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. Sep 1997;24(8):457-61. [Medline].

  17. Chanan-Khan A, Czuczman MS. Bcl-2 antisense therapy in B-cell malignant proliferative disorders. Curr Treat Options Oncol. Aug 2004;5(4):261-7. [Medline].

  18. Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, Ng CS. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. Jan 1998;16(1):70-7. [Medline].

  19. Cleary KR, Osborne BM, Butler JJ. Lymph node infarction foreshadowing malignant lymphoma. Am J Surg Pathol. Jul 1982;6(5):435-42. [Medline].

  20. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. Jan 24 2002;346(4):235-42. [Medline].

  21. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. Jan 1 2001;97(1):101-6. [Medline].

  22. Coltrera MD. Primary T-cell lymphoma of the thyroid. Head Neck. Mar 1999;21(2):160-3. [Medline].

  23. Cosset JM, Henry-Amar M, Meerwaldt JH, Carde P, Noordijk EM, Thomas J. The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer. 1992;28A(11):1847-50. [Medline].

  24. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. Dec 1994;12(12):2527-34. [Medline].

  25. Davis TA, White CA, Grillo-López AJ, Velásquez WS, Link B, Maloney DG. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol. Jun 1999;17(6):1851-7. [Medline].

  26. Dean RM, Bishop MR. Allogeneic hematopoietic stem cell transplantation for lymphoma. Clin Lymphoma. Mar 2004;4(4):238-49. [Medline].

  27. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. Jun 12 2003;348(24):2386-95. [Medline].

  28. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003;225-47. [Medline].

  29. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma--diagnosis and treatment. Lancet Oncol. Jan 2004;5(1):19-26. [Medline].

  30. DiGiuseppe JA, Corio RL, Westra WH. Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance. Curr Opin Oncol. May 1996;8(3):232-7. [Medline].

  31. Dunleavy K, Butrynski J, Steinberg S, et al. Phase II study of EPOCH infusional chemotherapy in relapsed or refractory Hodgkin's lymphoma (HL): a report on toxicity, efficacy and prognostic indicators of outcome. J Clin Oncol. 22:6598. [Full Text].

  32. Dunleavy K, Little R, Gea-Banacloche J. Abbreviated Treatment with Short-Course Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Is Highly Effective in AIDS-Related Lymphoma (ARL). Blood. 2004;104:3111. [Full Text].

  33. Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. Jun 1 2003;101(11):4285-9. [Medline].

  34. Ellison E, LaPuerta P, Martin SE. Supraclavicular masses: results of a series of 309 cases biopsied by fine needle aspiration. Head Neck. May 1999;21(3):239-46. [Medline].

  35. Engels EA, Chatterjee N, Cerhan JR, Davis S, Cozen W, Severson RK. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer. Aug 10 2004;111(1):76-80. [Medline].

  36. Ferreri AJ, Guidoboni M, Ponzoni M, De Conciliis C, Dell'Oro S, Fleischhauer K. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. Apr 21 2004;96(8):586-94. [Medline].

  37. Freedman AS, Nadler LM. Malignancies of lymphoid cells (Chapter 113). Harrison's Online. 1999;Part 6, Section 2.

  38. Friedberg JW, Freedman AS. High-dose therapy and stem cell transplantation in follicular lymphoma. Ann Hematol. May 1999;78(5):203-11. [Medline].

  39. Gilliam AC, Wood GS. Cutaneous lymphoid hyperplasias. Semin Cutan Med Surg. Jun 2000;19(2):133-41. [Medline].

  40. Gisselbrecht C. Autologous stem cell transplantation in aggressive non-Hodgkin's lymphoma. Hematol Cell Ther. Aug 1996;38(4):297-304. [Medline].

  41. Grufferman S, Cole P, Smith PG, Lukes RJ. Hodgkin's disease in siblings. N Engl J Med. Feb 3 1977;296(5):248-50. [Medline].

  42. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. Nov 1 2000;18(21):3633-42. [Medline].

  43. [Best Evidence] Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. Jul 1 2006;24(19):3121-7. [Medline].

  44. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. Dec 1999;17(12):3835-49. [Medline].

  45. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. Sep 1 1994;84(5):1361-92. [Medline].

  46. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. Nov 19 1998;339(21):1506-14. [Medline].

  47. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. Jan 15 2005;105(2):496-502. [Medline].

  48. Hiddemann W, Forstpointner R, Kneba M, et al. The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Ly. Blood. 2004;104:161. [Full Text].

  49. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. Feb 1 2002;20(3):630-7. [Medline].

  50. Horning SJ, Weller E, Kim K, Earle JD, O'Connell MJ, Habermann TM. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. Aug 1 2004;22(15):3032-8. [Medline].

  51. Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D. Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol. Mar 2000;18(5):972-80. [Medline].

  52. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol. Jan 1999;111(1 Suppl 1):S8-12. [Medline].

  53. Karmiris TD, Grigoriou E, Tsantekidou M, Spanou E, Mihalakeas H, Baltadakis J. Treatment of early clinically staged Hodgkin's disease with a combination of ABVD chemotherapy plus limited field radiotherapy. Leuk Lymphoma. Sep 2003;44(9):1523-8. [Medline].

  54. Kieserman SP, Finn DG. Non-Hodgkin's lymphoma of the external auditory canal in an HIV-positive patient. J Laryngol Otol. Aug 1995;109(8):751-4. [Medline].

  55. Kwak LW. Translational development of active immunotherapy for hematologic malignancies. Semin Oncol. Jun 2003;30(3 Suppl 8):17-22. [Medline].

  56. Landgren O, Björkholm M, Konradsen HB, Söderqvist M, Nilsson B, Gustavsson A. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma. J Intern Med. Jun 2004;255(6):664-73. [Medline].

  57. Lauer SA. Ocular adnexal lymphoid tumors. Curr Opin Ophthalmol. Oct 2000;11(5):361-6. [Medline].

  58. Lecuit M, Abachin E, Martin A. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med. Jan 15 2004;350(3):239-48. [Medline].

  59. Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol. Feb 2004;83(2):71-7. [Medline].

  60. Lenz G, Hiddemann W, Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer. Sep 1 2004;101(5):883-93. [Medline]. [Full Text].

  61. Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol. Feb 1998;16(2):584-8. [Medline].

  62. Little RF, Pittaluga S, Grant N. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. Jun 15 2003;101(12):4653-9. [Medline].

  63. Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol. Mar 1998;16(3):818-29. [Medline].

  64. Lohri A, Barnett M, Fairey RN, O'Reilly SE, Phillips GL, Reece D. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood. May 15 1991;77(10):2292-8. [Medline].

  65. Mack TM, Cozen W, Shibata DK, Weiss LM, Nathwani BN, Hernandez AM. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med. Feb 16 1995;332(7):413-8. [Medline].

  66. McCarthy H, Ottensmeier CH, Hamblin TJ, Stevenson FK. Anti-idiotype vaccines. Br J Haematol. Dec 2003;123(5):770-81. [Medline].

  67. Mendenhall NP. The role of radiation in the management of Hodgkin's disease: an update. Cancer Invest. 1999;17(1):47-55. [Medline].

  68. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. Jul 2 1998;339(1):21-6. [Medline].

  69. Nathu RM, Mendenhall NP, Almasri NM, Lynch JW. Non-Hodgkin's lymphoma of the head and neck: a 30-year experience at the University of Florida. Head Neck. May 1999;21(3):247-54. [Medline].

  70. Ng AK, Li S, Neuberg D, Silver B, Stevenson MA, Fisher DC. Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease. Ann Oncol. Feb 2004;15(2):270-5. [Medline]. [Full Text].

  71. Pfreundschuh M, Trumper L, Kloess M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. Aug 1 2004;104(3):626-33. [Medline].

  72. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. Aug 1 2004;104(3):626-33. [Medline].

  73. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. Aug 1 2004;104(3):634-41. [Medline].

  74. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. Aug 1 2004;104(3):634-41. [Medline].

  75. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. May 2006;7(5):379-91. [Medline].

  76. Poiesz BJ, Papsidero LD, Ehrlich G, Sherman M, Dube S, Poiesz M. Prevalence of HTLV-I-associated T-cell lymphoma. Am J Hematol. Jan 2001;66(1):32-8. [Medline].

  77. Pratt BL, Greene FL. Role of laparoscopy in the staging of malignant disease. Surg Clin North Am. Aug 2000;80(4):1111-26. [Medline].

  78. Prosnitz LR, Farber LR, Kapp DS, Scott J, Bertino JR, Fischer JJ. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. J Clin Oncol. Apr 1988;6(4):603-12. [Medline].

  79. Reece DE. Evidence-based management of Hodgkin's disease: the role of autologous stem cell transplantation. Cancer Control. May-Jun 2000;7(3):266-75. [Medline].

  80. Rehm PK. Gallium-67 scintigraphy in the management: Hodgkin's disease and non-Hodgkin's lymphoma. Cancer Biother Radiopharm. Aug 1999;14(4):251-62. [Medline].

  81. Ries LA, Eisner MP, Kosary CL, et al, eds. SEER cancer statistics review 1973-1998. Available at: http://seer.cancer.gov/. Bethesda, MD: National Cancer Institute. 2001. [Full Text].

  82. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. Oct 1 2005;23(28):7013-23. [Medline].

  83. Santini G, Chisesi T, Nati S, Porcellini A, Zoli V, Rizzoli V. Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group. Leuk Lymphoma. Jun 2004;45(6):1141-7. [Medline].

  84. Schnell R, Borchmann P, Schulz H, Engert A. Current strategies of antibody-based treatment in Hodgkin's disease. Ann Oncol. 2002;13 Suppl 1:57-66. [Medline].

  85. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol. Aug 2000;18(15):2908-25. [Medline].

  86. Sohn SK, Baek JH, Kim DH, Jung JT, Kwak DS, Park SH. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL. Am J Hematol. Sep 2000;65(1):75-80. [Medline].

  87. Spicer J, Smith P, Maclennan K, Hoskin P, Hancock B, Linch D, et al. Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin's lymphoma. Br J Cancer. Mar 22 2004;90(6):1151-5. [Medline].

  88. Staudt MR, Kanan Y, Jeong JH, Papin JF, Hines-Boykin R, Dittmer DP. The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res. Jul 15 2004;64(14):4790-9. [Medline]. [Full Text].

  89. Stewart FM. Indications and relative indications for stem cell transplantation in non-Hodgkin's lymphoma. Leukemia. Jul 1993;7(7):1091-4. [Medline].

  90. Ströhmann B, Haake K. [Nasal cavity and paranasal sinus malignancies in the ENT clinic of Charité since 1959]. Laryngorhinootologie. Mar 1991;70(3):138-41. [Medline].

  91. Terry JH, Loree TR, Thomas MD, Marti JR. Major salivary gland lymphoepithelial lesions and the acquired immunodeficiency syndrome. Am J Surg. Oct 1991;162(4):324-9. [Medline].

  92. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Boutsis DE, et al. Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy. Eur J Haematol. May 2002;68(5):289-98. [Medline].

  93. Viviani S, Santoro A, Negretti E, Bonfante V, Valagussa P, Bonadonna G. Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission. Ann Oncol. 1990;1(2):123-7. [Medline].

  94. Wilson WH, Dunleavy K, Pittaluga S, et al. DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6- Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers. ASH Annual Meeting Abstracts. 2006;206:108.

  95. Wilson WH, Grossbard ML, Pittaluga S. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. Apr 15 2002;99(8):2685-93. [Medline].

  96. Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. Jun 1 2006;107(11):4207-13. [Medline].

  97. Wirth A, Wolf M, Prince HM. Current trends in the management of early stage Hodgkin's disease. Aust N Z J Med. Aug 1999;29(4):535-44. [Medline].

  98. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. Aug 1 2002;20(15):3262-9. [Medline].

  99. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. May 15 2002;20(10):2453-63. [Medline].

  100. Wotherspoon AC. Gastric lymphoma of mucosa-associated lymphoid tissue and Helicobacter pylori. Annu Rev Med. 1998;49:289-99. [Medline].

  101. Yu KH, Yu SC, Teo PM, Chan AT, Yeo W, Chow J. Nasal lymphoma: results of local radiotherapy with or without chemotherapy. Head Neck. Jul 1997;19(4):251-9. [Medline].

  102. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood. Feb 1 1997;89(3):814-22. [Medline]. [Full Text].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

lymphomas of the head and neck, Hodgkin lymphoma, Hodgkin's lymphoma, HL, non-Hodgkin lymphoma, non-Hodgkin's lymphoma, NHL, nonHodgkin lymphoma, B-cell lymphomas, Reed-Sternberg cells, RS cells

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Kieron M Dunleavy, MD, Investigator/Attending Physician, National Cancer Institute
Kieron M Dunleavy, MD is a member of the following medical societies: American Society of Hematology
Disclosure: Nothing to disclose.

Coauthor(s)

Erik Kass, MD, Chief, Department of Clinical Otolaryngology, Associates in Otolaryngology of Northern Virginia
Erik Kass, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Association for Cancer Research, American Medical Association, and American Rhinologic Society
Disclosure: Nothing to disclose.

Wyndham Wilson, MD, PhD, Senior Investigator, Division of Clinical Sciences, National Institutes of Health National Cancer Institute
Disclosure: Nothing to disclose.

Medical Editor

Daniel J Kelley, MD, Consulting Staff, Eastern Shore ENT and Allergy Associates and Peninsula Regional Medical Center
Daniel J Kelley, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, American Laryngological Rhinological and Otological Society, and Pennsylvania Medical Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Karen Hall Calhoun, MD, Professor, Department of Otolaryngology-Head and Neck Surgery, The Ohio State University
Karen Hall Calhoun, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, American Medical Association, American Rhinologic Society, Association for Research in Otolaryngology, Society of University Otolaryngologists-Head and Neck Surgeons, Southern Medical Association, Texas Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

CME Editor

Christopher L Slack, MD, Otolaryngology-Facial Plastic Surgery, Private Practice, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders
Christopher L Slack, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine
Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society
Disclosure: Covidien Corp Consulting fee Consulting; US Tobacco Corporation unstricted gift unknown; Axis Three Corporation Ownership interest Consulting; Omni Biosciences Ownership interest Consulting; Sentegra Ownership interest Board membership; Syndicom Ownership interest Consulting; Oxlo  Consulting; Medvoy Ownership interest Management position

RELATED MEDSCAPE ARTICLES
Articles
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.